Desialylation of platelets induced by Von Willebrand Factor is a novel mechanism of platelet clearance in dengue by Riswari, S.F. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/202895
 
 
 
Please be advised that this information was generated on 2019-06-02 and may be subject to
change.
RESEARCH ARTICLE
Desialylation of platelets induced by Von
Willebrand Factor is a novel mechanism of
platelet clearance in dengue
Silvita Fitri RiswariID1,2,3☯, Rahajeng N. TunjungputriID2,3,4☯, Vesla KullayaID2,3,5☯, Fadel
M. Garishah2,3,4, Gloria S. R. Utari4, Nur Farhanah4, Gijs J. Overheul4,6,
Bachti Alisjahbana1, M. Hussein Gasem4, Rolf T. Urbanus7, Philip. G. de Groot3, Dirk
J. Lefeber8, Ronald P. van RijID3,6, Andre van der VenID2,3, Quirijn de Mast2,3*
1 Clinical Infectious Disease Research Center, Faculty of Medicine, Universitas Padjadjaran, Bandung,
Indonesia, 2 Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The
Netherlands, 3 Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, The
Netherlands, 4 Center for Tropical and Infectious Disease (CENTRID), Faculty of Medicine Diponegoro
University, Dr Kariadi Hospital, Semarang, Indonesia, 5 Kilimanjaro Christian Medical Center, Kilimanjaro
Clinical Research Institute, Moshi, Tanzania, 6 Department of Medical Microbiology, Radboud Institute for
Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands, 7 Department of
Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht University, Utrecht, The
Netherlands, 8 Department of Neurology, Translational Metabolic Laboratory, Radboud University Medical
Center, Nijmegen, The Netherlands
☯ These authors contributed equally to this work.
* quirijn.demast@radboudumc.nl
Abstract
Thrombocytopenia and platelet dysfunction are commonly observed in patients with dengue
virus (DENV) infection and may contribute to complications such as bleeding and plasma
leakage. The etiology of dengue-associated thrombocytopenia is multifactorial and includes
increased platelet clearance. The binding of the coagulation protein von Willebrand factor
(VWF) to the platelet membrane and removal of sialic acid (desialylation) are two well-
known mechanisms of platelet clearance, but whether these conditions also contribute to
thrombocytopenia in dengue infection is unknown. In two observational cohort studies in
Bandung and Jepara, Indonesia, we show that adult patients with dengue not only had
higher plasma concentrations of plasma VWF antigen and active VWF, but that circulating
platelets had also bound more VWF to their membrane. The amount of platelet-VWF bind-
ing correlated well with platelet count. Furthermore, sialic acid levels in dengue patients
were significantly reduced as assessed by the binding of Sambucus nigra lectin (SNA) and
Maackia amurensis lectin II (MAL-II) to platelets. Sialic acid on the platelet membrane is
neuraminidase-labile, but dengue virus has no known neuraminidase activity. Indeed, no
detectable activity of neuraminidase was present in plasma of dengue patients and no
desialylation was found of plasma transferrin. Platelet sialylation was also not altered by in
vitro exposure of platelets to DENV nonstructural protein 1 or cultured DENV. In contrast,
induction of binding of VWF to glycoprotein 1b on platelets using the VWF-activating protein
ristocetin resulted in the removal of platelet sialic acid by translocation of platelet neuramini-
dase to the platelet surface. The neuraminidase inhibitor oseltamivir reduced VWF-induced
platelet desialylation. Our data demonstrate that excessive binding of VWF to platelets in
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dengue results in neuraminidase-mediated platelet desialylation and platelet clearance.
Oseltamivir might be a novel treatment option for severe thrombocytopenia in dengue
infection.
Author summary
Dengue is the most common arbovirus infection in the world. A decrease in the number
of blood platelets is an almost universal finding in severe dengue. Binding of the coagula-
tion protein von Willebrand factor (VWF) and loss of sialic acid residues from the platelet
membrane are two main mechanisms of clearance of senescent platelets under non-patho-
logical conditions. Here, we show that platelets from patients with acute dengue have
bound more VWF and have lost sialic acid from their membrane. Sialic acid can be
cleaved by the enzyme neuraminidase. We show that neuraminidase activity in the plasma
is not increased and that neither dengue virus itself nor nonstructural protein 1, a protein
secreted by dengue virus, cleave sialic acid from the platelet membrane. In contrast, bind-
ing of VWF to platelets results in translocation of neuraminidase to the platelet membrane
and subsequent cleavage of sialic acid. This process could be inhibited by the neuramini-
dase inhibitor oseltamivir, a commonly used anti-influenza drug. Altogether, our results
indicate that VWF binding to platelets is increased in dengue infection, leading to the
removal of sialic acid and platelet clearance. Oseltamivir may prevent this process and
thus represent a novel treatment option for low platelet numbers in dengue infection.
Introduction
Dengue is the most common arboviral infection in the world with an estimated number of 390
million annual cases, of which 96 million manifests with symptomatic disease [1]. A subset of
patients with symptomatic infections develops potentially life-threatening complications in
which bleeding and vascular plasma leakage are the most common [2]. To date, there is no
curative therapy for dengue and clinical observation and treatment of complications remain
the core principles of dengue management.
Thrombocytopenia is an early and consistent feature of dengue virus infection [3–6] and
dengue complications are usually preceded by a rapid drop in platelet count [2]. Traditionally
known for their key role in hemostasis, platelets are nowadays well known to have important
additional functions, including regulation of inflammation and host defense [7–9] and preser-
vation of endothelial integrity [10], especially under inflammatory conditions [11].
Circulating platelets of dengue patients are activated and excessive platelet activation may
lead to platelet exhaustion [12–15], which likely contributes to thrombocytopenia and dengue
complications. Other well-known mechanisms of increased platelet clearance under non-path-
ological conditions are the binding of von Willebrand factor (VWF) to platelets and loss of
sialic acids from the platelet membrane [16]. VWF is a multimeric protein that is present in
plasma, platelets, and endothelial cells. Endothelial activation results in the release of VWF
from Weibel-Palade bodies into the blood circulation. Its primary function is platelet adhesion
and aggregation at sites of vessel injury [17]. The antibiotic ristocetin induces binding of VWF
to platelets and may cause thrombocytopenia, and as a consequence, it was removed from clin-
ical practice [18]. We have previously shown that the plasma of children with severe dengue
contains increased levels of circulating VWF in an active–platelet binding–conformation and
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increased VWF proteolysis [19]. Importantly, enhanced VWF binding to platelets—as seen in
von Willebrand disease (VWD) type 2B - was shown to induce phagocytosis of VWF/platelet
complexes by macrophages in the liver and spleen and promote thrombocytopathy by inhibi-
tion of platelet integrin αIIbβ3, the platelet fibrinogen receptor [20, 21]. Increased platelet
phagocytosis, as well as impaired platelet αIIbβ3 function, have also been described in patients
with dengue [15, 22].
Most platelet glycoproteins, including the extracellular domains of Glycoprotein 1bα
(GPIbα; ‘the major VWF receptor’), are decorated with N-glycans and O-linked glycans,
which are covered by sialic acids [23, 24], a family of monosaccharides with a 6-carbon back-
bone. Loss of terminal sialic acids, which can be mediated by human sialidase neuraminidase 1
(NEU1) or exogenous sialidase, exposes β-galactose and β-N-acetyl-D glucosamine (β-
GlcNAc), which can be recognized by macrophages or the hepatic asialoglycoprotein receptor
(ASGPR; also called the Ashwell–Morell receptor) [25–28]. Recently, binding of VWF to
GPIbα under physiological shear was shown to induce platelet desialylation [29].
The aim of our study was to investigate these platelet clearance processes during the course
of the disease in patients with dengue and their relationship with thrombocytopenia and plate-
let reactivity. We first show that dengue is associated with increased binding of VWF to plate-
lets. In a follow up clinical study, we also show that circulating platelets have markedly
reduced surface sialic acid. Both VWF binding and desialylation were associated with throm-
bocytopenia. In a set of ex vivo studies, we then show that VWF binding to platelets leads to
NEU-1 mediated desialylation, which can be inhibited by the sialidase inhibitor oseltamivir.
Materials and methods
Patients and study design
Two observational clinical studies were performed in Indonesian patients with acute dengue
and conducted according to the principles expressed in the Declaration of Helsinki. In study 1,
the binding of VWF to circulating platelets was investigated and related to thrombocytopenia
and platelet reactivity. In study 2, sialic acid on the platelet surface was determined. Both stud-
ies were exploratory in nature and therefore no sample size calculation was performed.
Clinical study 1. This study was conducted in Hasan Sadikin general hospital and Sala-
mun Hospital in Bandung between January to June 2015. Febrile patients (�37.5˚C) aged� 1
year old, with clinically suspected acute dengue infection, thrombocytopenia (platelet count
<150 x 109/l), and a positive result of either a dengue non-structural protein 1 (NS1) rapid test
(PanBio Dengue Early Rapid, Alere), DENV in-house RT-PCR and/or dengue IgM (PanBio
Dengue Duo cassette, Alere) were enrolled. Patients with chronic diseases, use of antiplatelet
drugs or pregnancy were excluded. Medical history and physical examination were performed
daily with special emphasis on bleeding manifestations and plasma leakage. Blood was drawn
at admission and during the course of the infection, in which day 1–3 after onset of fever cor-
responds roughly with the febrile phase, day 4–6 with the critical phase, and day 7–13 with the
recovery phase of a dengue infection [2, 30]. Convalescent samples were also taken >13 days
after fever onset. Plasma leakage was defined as an increase in hematocrit of� 20%, a single
high hematocrit value (> 50% for men and> 44% for women), or by plasma leakage in the
form of ascites or pleural effusion as determined by daily handheld ultrasonography, as
described previously [31]. A group of healthy volunteers was recruited among hospital staff to
serve as controls. None of the controls experienced a fever or other complaints in the past
month and all had a normal complete blood count.
Clinical study 2. This study was performed from January to March 2016 in Kartini Hospi-
tal, a district hospital in Jepara, Central Java. Febrile patients clinically suspected of acute
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dengue infection with one of the following diagnostic criteria were enrolled: aged� 5 years,
positive NS1 test (PanBio Dengue Early Rapid, Alere), positive results of dengue-specific IgM
or seroconversion for dengue-specific IgM or IgG (PanBio Dengue Duo cassette, Alere).
Patients with chronic diseases, use of antiplatelet drugs or pregnancy were excluded. Two
blood samples were drawn for this study: one sample at the critical phase or early recovery
phase and one sample at the convalescence phase. Two control groups were enrolled: one
group of patients with non-dengue febrile illness and a group of adult healthy volunteers
recruited among hospital staff.
Ethics statement
The first clinical study was approved by the local Medical Ethical Committee of the Medical
Faculty of Padjadjaran University, Hasan Sadikin General Hospital. The second clinical study
was approved by the local Medical Ethical Committee of the Faculty of Medicine, Diponegoro
University, and Kartini Hospital. In both clinical studies, written informed consent was
obtained before enrolment from all patients and healthy controls, and in the case of pediatric
subjects, a parent or guardian provided written informed consent on behalf of the child.
Laboratory assays clinical studies
Platelet reactivity and VWF binding to platelets. Venous blood was collected in 3.2%
citrate anti-coagulated vacutainers (BD Biosciences). Platelet activation and reactivity were
determined by flow cytometry using a method previously described [32]. Briefly, the platelet
membrane expression of P-selectin (CD62P) and platelet-fibrinogen binding, which corre-
spond with platelet degranulation and aggregation, respectively, were determined in unstimu-
lated whole blood and after ex vivo stimulation with the platelet agonists adenosine-
diphosphate (ADP; 7.8 μM and 31.2 μM) (Sigma-Aldrich, Zwijndrecht, The Netherlands) or
PAR-1 agonist thrombin receptor-activating peptide (TRAP; 39 μM and 156.25 μM or
625 μM) (Sigma-Aldrich, Zwijndrecht, the Netherlands). VWF binding to platelets in whole
blood was measured as previously described [32]. Briefly, whole blood was incubated with a
mixture of HEPES-buffered saline and saturating concentrations of FITC-labeled anti-VWF
(Abcam, Cambridge, UK) and PC7-labeled anti-CD61 (eBioscience), with or without the addi-
tion of ristocetin (0.433 μM, 0.577 μM and 0.77 μM) (American biochemical & pharmaceuti-
cals). After incubation for 20 minutes at room temperature, a fixative solution (0.2%
paraformaldehyde) was added. Samples were measured on a BD FACS Calibur (Bandung) or
BD FACS Canto II (Jepara). Platelets were gated based on their forward- and sideward-scatter
(FSC/SSC) properties and positivity for CD42b or CD61, which was defined as a median fluo-
rescence intensity (MFI) exceeding the MFI of the matched isotype control.
Platelet surface sialic acid. Citrated whole blood was immediately centrifuged after blood
drawing for 15 minutes at 300 g without brake to obtain platelet-rich plasma (PRP). Four million
platelets were resuspended in 100 μl PBS in an Eppendorf tube and centrifuged for 8 minutes at
600 g. The platelet pellet was then stained with the platelet identification marker CD61 (anti-61
PC7, Beckman Coulter, Woerden, Netherlands) and streptavidin labelled sialic acid binding lec-
tins Sambucus nigra lectin (SNA) and Maackia amurensis lectin II (MAL-II) (both obtained from
Vector Laboratories, California, USA) for 30 minutes at room temperature (RT). Cells were then
washed, fixated using 0.2% paraformaldehyde (PFA) and analyzed using flow cytometer.
Plasma markers. Plasma VWF antigen (VWF:Ag) and active VWF levels were deter-
mined with ELISA, as described previously [33]. Nunc maxisorb 96 wells ELISA plates were
coated overnight at 4˚C with 0.775 μg/ml anti-total VWF IgG (DAKO, A0082) or 5 μg/ml of
anti-active VWF VHH (AU/VWF-a11). Diluted plasma samples were incubated for one hour
Desialylation as a novel platelet clearance mechanism in dengue
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007500 March 8, 2019 4 / 22
at room temperature. Plates were washed three times and incubated with 0.55 ug/mL poly-
clonal rabbit anti-human VWF to capture VWF and active VWF for one hour at 37˚C. Bind-
ing was detected with HRP-conjugated rabbit anti-mouse antibody. HRP activity was
measured using OPD as a substrate after 30 minutes incubation at 37˚C. Normal pooled
plasma (NPP) was used as a standard in every assay. ADAMTS-13 activity was determined
using the fluorescence resonance energy transfer (FRETS) assay for ADAMTS-13 activity
(Peptides International, Inc. USA) whereby the ADAMTS-13 activity of NPP of the healthy
Dutch donors was set at 100% [34]. Values obtained in the study participant samples were
expressed as a percentage of NPP.
Plasma neuraminidase activity and transferrin glycosylation. Sialidase activity in
plasma of participants in the Jepara cohort was determined with a fluorometric method with
0.45 mM 2-(4-methylumbelliferyl)α-D-N-acetylneuraminic acid as a substrate, as previously
described [35]. In this assay, 30 μl plasma was mixed with equal volumes of substrate and reac-
tion buffer of pH 7.0 and incubated at 37˚C for 2 hrs. After incubation 400μl of stop solution
(containing glycine and trisol) was added. The mixture was vortexed and centrifuged at 10,000
x g for 10 minutes. 300μl of the supernatant was transferred to a clean reaction plate and fluo-
rescence was measured. Enzymatic activity was calculated in moles of substrate hydrolyzed per
unit per time (hours). Plasma sialidase activity was also investigated by mixing platelet rich
plasma (PRP) from healthy Dutch volunteers with platelet poor plasma (PPP) from partici-
pants in the Jepara cohort in a volume ratio of 1:1 for two hours at 37˚C. Desialylation of plate-
lets was analyzed by staining platelets with sialic acid binding lectins SNA and MAL-II as
described above.
Transferrin glycosylation in plasma of dengue patients was analyzed using high-resolution
nano liquid chromatography-chip (C8) quadrupole time of flight mass spectrometry
(nanoLC-chip [C8]-QTOF MS) as previously described [35]. Briefly, plasma samples were
diluted 1:10 with 0.9% NaCl solution and loaded onto a pierce spin column (Thermo Fisher)
containing anti-transferrin conjugated beads. Samples were incubated for 15 minutes at room
temperature, followed by 6 washing steps of 700 μl 10 mM Tris-HCl, pH 7 and a single elution
(50 μl, 100 mM glycine-HCl, pH 2.7). The eluted fraction was neutralized with 1–1.5 μl 1.0 M
Tris-HCl, pH 9.0 and analyzed on a microfluidic 6540 HPLC-chip-QTOF instrument (Agilent
Technologies). Peak abundances were listed by Agilent BioConfirm Software and were used to
calculate the ratio of sialylation by expressing the percentage of trisialotransferrin in compari-
son with tetrasialotransferrin (the most abundant transferrin isoform in controls).
In vitro studies
Platelet preparation. PRP and washed platelets were isolated from 3.2% sodium-citrate-
anticoagulated whole blood from healthy volunteers as previously described [36]. Briefly,
whole blood was centrifuged for 15 minutes at 156xg without a brake to obtain PRP. PRP was
further centrifuged at 330xg for 15 minutes to obtain platelets poor plasma (PPP) and platelet
pellets, which were resuspended in HEPES tyrode buffer at 4x108 platelets/ml.
Dengue NS1 and dengue virus. Washed platelets (1x107 plt/ml) were exposed to different
concentrations (1.25–10 μg/ml) of NS1 protein from dengue virus serotype 2 (DENV2, strain
Thailand/16681/84) (Native Antigen, Oxfordshire, United Kingdom) and incubated for 4
hours at 37˚C. This NS1 protein is in its native hexamer folding state and possess all post-
translational modifications. It is shown to be> 95% pure and oligomeric, as demonstrated by
native PAGE and Western blot analysis [37][38] and as certified by the manufacturer. In addi-
tion, washed platelets were exposed to DENV2 strain 16681 (kind gift from Claire Huang,
Centers for Disease Control, Fort Collins, CO, USA). Virus stock was prepared in the Aedes
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albopictus mosquito-derived C6/36 cell line to exclude the possibility that mammalian cyto-
kines and other inflammatory products in the virus stock would influence the results. Virus
was cultured using Leibovitz’s L-15 medium (Thermo Fisher) supplemented with 10% heat-
inactivated fetal calf serum (Thermo Fisher), 2% Tryptose Phosphate Broth Solution (Sigma),
1x MEM Non-Essential Amino Acids (Thermo Fisher), and 50 U/ml penicillin and 50 μg/ml
streptomycin (Thermo Fisher). Briefly, cells were infected with DENV2 and after 2 hours of
incubation at 28˚C, the medium was replaced with fresh L-15 medium. The cells were incu-
bated at 28˚C and the supernatant was harvested 4 days post-infection, stored in aliquots at
−80 ˚C, and titrated on BHK-15 cells by end-point dilution. Supernatant of uninfected C6/36
cells was harvested in parallel to virus stocks, for use in mock infections. Washed platelets
(1x107 plt/ml) were inoculated with DENV2 at a multiplicity of infection (MOI) of 3.7, or with
an equal volume of mock medium, incubated for 3 or 6 hours, followed by fixation with 1%
PFA to inactive DENV. Surface sialic acid was measured as described above. PFA fixation had
no effect on lectin binding to sialic acid on the platelet membrane. Purified neuraminidase
(NA; 200μM) from Clostridium perfringens (Sigma-Aldrich, Zwijndrecht, Netherlands) was
used as positive control.
Induction of VWF-platelet binding and effect of oseltamivir. Binding of VWF to plate-
lets was induced by exposing PRP to different concentrations of ristocetin (0–1.6 mg/ml)
(American Biochemical & Pharmaceuticals, Epsom, UK) for 1hr at 37˚C. VWF-platelet bind-
ing was inhibited in selected experiments by pre-incubation of PRP with 5μg/ml anti-GP1b
antibodies (Abbiotec, San Diego, CA) for 30 minutes. In selected experiments, inhibition of
platelet desialylation by neuraminidase inhibitors was investigated by incubation of PRP with
1–50 μM oseltamivir acid (Santa Cruz Biotechnology, Texas, USA) for 30 minutes. Plasma-
derived VWF was purified from Haemate P by gel filtration chromatography as previously
described [39]. The VWF was quantified using VWF antigen ELISA.
Flow cytometry. Surface sialic acid was measured using the lectins SNA and MAL-II as
described above. In selected experiments, surface galactose expression was analyzed by incuba-
tion with streptavidin labeled Ricinus communis agglutinin 1 (RCA-1) lectin (vector laborato-
ries, California, USA). Neuraminidase expression on the platelet surface was measured using
antibodies against human neuraminidase-1 (anti-neu-1, Fisher scientific, Landsmeer, The
Netherlands) as primary antibody and Goat-anti-rabbit IgG–Alexa Fluor 488 (Fischer scien-
tific) as secondary antibody. Platelet VWF and expression of the lysosomal marker CD63 were
measured with the following antibodies: anti-VWF FITC (Abcam, Cambridge, UK), anti-
CD63 FITC, (Biolegend, San Diego, CA) and anti-CD61 PC7 (Beckman Coulter) as platelet
identification marker. Platelets were incubated with saturating amounts of these antibodies for
25 minutes, fixated with 0.2% PFA for 15 minutes and measured on a Cytomics FC500 flow
cytometer or a Cytoflex flow cytometer (both Beckman Coulter).
Statistical analysis
Statistical analyses were performed using GraphPad Prism 5 software. Data are presented as
geometric mean with 95% confidence intervals unless stated otherwise. The Kruskal Wallis
test was used to determine significance between multiple groups. Differences between individ-
ual groups were analyzed with the Mann-Whitney test or Student’s T-test. Correlations were
tested using either the Spearman correlation test (for non-normally distributed data) or Pear-
son correlation test (normally distributed data). A P value<0.05 was considered a statistically
significant difference. Flow cytometry data were analyzed with Beckman Coulter Kaluza soft-
ware, version 1.2. Data on transferrin glycosylation were analyzed with Agilent Mass Hunter
Qualitative Analysis Software B.04.00.
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Results
Clinical characteristics and platelet number and reactivity
In Bandung, a total number of 40 patients with acute dengue and 10 healthy adult controls
were enrolled. Three patients were children aged�14 years old. Samples collected were
divided into four groups based on the day of fever; day 1–3 (n = 20), day 4–6 day (n = 54), day
7–13 (n = 24) and day >13 days (n = 24). In Jepara, 40 patients with dengue were enrolled,
together with 15 patients with non-dengue illness (acute gastroenteritis n = 9, acute respiratory
tract infection n = 6) and 25 healthy controls. Ten and three of the patients with dengue or
non-dengue febrile illness respectively were children. Clinical characteristics are given in
Table 1. Hemorrhagic manifestations were common in both dengue cohorts (35% in Bandung
and 38% in Jepara) and manifested predominantly as skin or mucosal bleeding. Ultrasonogra-
phy was performed routinely in the Bandung cohort during the critical phase showing ascites,
pleural effusion or a thickened gallbladder in 33 (82.5%) of the enrolled patients.
Fig 1A and 1B shows platelet numbers in the Bandung and Jepara cohorts. Platelets num-
bers in healthy controls were not determined. As expected, platelet numbers were lowest on
day 4–6 after onset of fever, which roughly corresponds with the critical phase of dengue. Fig
1C–1F shows data of platelet activation and reactivity to ex vivo stimulation with the platelet
agonist ADP. Compared with healthy controls, circulating platelets of dengue patients were
activated on day 1–3 and day 4–6 after fever onset, as shown by increased expression of P-
selectin and fibrinogen binding to integrin αIIbβ3. In conjunction with this, ex vivo reactivity
to stimulation with ADP was significantly reduced on these days compared with later phases
and healthy controls, indicating platelet dysfunction. Similar findings were found for platelet
Table 1. Clinical characteristics cohorts Bandung and Jepara.
Bandung Jepara
Variable Dengue Controls Dengue Non-dengue illness Controls
Number 40 10 40 15 25
Male, n, (%) 27 (68) 4 (40) 21 (53) 6 (40) 14 (56)
Age, years, median (IQR) 22 (17–35) 27 (17–35) 20 (15–39) 26 (12–33) 28 (26–34)
Days of fever at presentation, median (IQR) 4 (3–5)� NA 4.0 (2–6) 4.1 (2–6) NA
NS1 positive, n (%) 38 (95) NA 16 (40) 0 (0) NA
Bleeding manifestations, n (%) 14 (35) NA 15 (38) 0 (0) NA
Bleeding type, n (%) NA NA
Petechia 3 (7.5) 7 (17.5)
Gum bleeding 8 (20.0) 5 (12.5)
Epistaxis 5 (12.5) 6 (15)
Melena 2 (5.0) 3 (7.5)
Hypermenorrhea 1 (2.5) 0 (0)
Classification, n (%)#
DF 8 (20) NA 25 (62) NA NA
DHF 32 (80) NA 15 (38) NA NA
Full blood count at presentation, median (IQR)�
Hemoglobin, gr/dL 14.2 (13.5–15.2) 13.4 (12.7–16.1) 13.8 (12.4–14.1) 13.6 (12.8–13.9) 13.9 (12.9–14.2)
Platelet count, 109/L 62 (34–101) 265 (237–312) 46 (29–72) 152 (104–211) 261 (197–309)
Hematocrit, % 42.0 (40.0–44.8) 41.0 (38.3–46.3) 41.7 (38.1–41.8) 42.2 (37.7–42.8) NA
# DF, dengue fever; DHF, dengue hemorrhagic fever (defined as dengue with hemorrhagic manifestations, plasma leakage, and platelet count <100x109/L)
NA, not applicable
https://doi.org/10.1371/journal.ppat.1007500.t001
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reactivity towards the platelet agonist TRAP (S1 Fig). These findings confirm our earlier find-
ings that platelets in patients with dengue are activated, but also functionally impaired [15].
Increased VWF binding to platelets
Plasma levels of active VWF levels are increased in patients with dengue [19], but it is
unknown whether this results in higher binding of VWF to platelets. We, therefore, deter-
mined the binding of VWF to platelets in the Bandung cohort using flow cytometry. We
observed a significantly (P<0.001) higher binding of VWF to circulating platelets of patients
in the acute or critical phase of dengue compared to healthy controls (Fig 2A; gating strategy
shown in S2 Fig). When plasma VWF was further activated by ex vivo incubation of whole
blood with different concentrations of ristocetin, VWF-platelet binding increased. Higher val-
ues were obtained in the febrile and critical phase than in the convalescence phase and in
healthy controls (Fig 2B). Median plasma VWF antigen (VWF:Ag) concentrations were
approximately three fold higher in patients in the acute phase than in controls (median, (IQR);
27.9 μg/ml (21.6–38.8 μg/ml) vs. 8.4 μg/ml (4.4–14.1 μg/ml); P< 0.01) and remained elevated
throughout the convalescent phase (Fig 2C). Plasma concentrations of active VWF, which
means VWF in which the platelet binding epitope on the A1 domain is exposed, were two-fold
higher in the acute phase than in controls (median (IQR) 629 ng/ml (461–860 ng/ml) vs. 300
ng/ml (151–319 ng/ml); P<0.01) (Fig 2D). Levels of ADAMTS-13, an enzyme that cleaves pro-
thrombotic ultra-large VWF, was significantly lower in patients around the critical phase (day
4–6 after fever onset) compared with the convalescent phase (day >13) and healthy controls
(S3 Fig).
Platelet-VWF binding was inversely correlated with platelet numbers in enrolment samples
(Pearson R = -0.59; P< 0.001) (Fig 2E). Increased VWF-platelet GP1b interaction was reported
to be associated with inhibition of platelet αIIbβ3 [21], but we found no correlation between
platelet-VWF binding and TRAP- or ADP-induced platelet fibrinogen binding (Fig 2F, data
high dose TRAP shown). There was also no correlation between platelet-VWF binding and
plasma VWF levels (R = -0.09; P = 0.68), active VWF levels (R = 0.08; p = 0.69) or ADAMTS-
13 levels (R = -0.19; P = 0.39) (S3 Fig). These results show for the first time that VWF binding
to platelets is a feature of dengue which may contribute to dengue-associated
thrombocytopenia.
Finally, we compared platelet parameters between patients with and without bleeding, as
well as those with and without plasma leakage. No significant differences in platelet count,
platelet-VWF binding, plasma VWF and active VWF levels were found between subjects with
or without bleeding complications and between those with or without plasma leakage, except
for a significantly higher plasma VWF in the in the plasma leakage group (S4 Fig).
Platelet desialylation in dengue infection
Next, in the Jepara cohort, we determined whether there was also loss of sialic acid from the
platelet membrane in dengue infection. Platelet surface sialic acid was measured in patients in
the critical or early recovery phase of dengue (median 7 days after fever onset) using the lectins
SNA and MAL-II, which primarily binds α-2,6-sialoglycans and MAL-II α-2,3-sialoglycans,
Fig 1. Platelet number and platelet activation with impaired reactivity in patients with dengue infection. (A, B) Platelet number at enrolment in
cohorts from Bandung and Jepara. Binding of fibrinogen (C, D) to platelets and platelet P-selectin expression (E, F) in unstimulated samples and after ex
vivo stimulation with two concentrations of ADP. Platelet P-selectin expression and binding of fibrinogen were measured using flow cytometry and are
expressed as median fluorescence intensity (MFI) in arbitrary units. Data depicted as geometric mean with 95% confidence interval. Differences between
groups were analyzed using the Mann-Whitney U test, �P< 0.05, �� P<0.01, ���P<0.001.
https://doi.org/10.1371/journal.ppat.1007500.g001
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respectively. The median (IQR) platelet count at the time of measurement was 57 (37–81)
x109/L. Binding of both lectins to sialic acid residues was significantly reduced in patients with
dengue, compared with patients with non-dengue febrile illness and healthy controls (Fig 3A
and 3B; gating strategy shown in S5 Fig). In 12 participants, SNA and MAL-II binding was
also measured in the convalescence phase when platelets numbers had normalized. Both plate-
let SNA and MAL-II had increased significantly compared with the early dengue phase with
median MFI values for SNA of 762 (663–857) vs. 537 (439–752; P = 0.003; Wilcoxon signed
rank test) and for MAL-II of 6246 (5171–7188) vs. 5096 (4435–6004; P = 0.001). In the early
dengue phase, platelet count correlated significantly with SNA binding (Spearman R 0.48;
P = 0.002), but not with MAL-II binding (R 0.28; P = 0.08). In addition, there was also no cor-
relation between SNA or MAL-II binding and levels of VWF:Ag (SNA R = -0.2; P = 0.25 and
MAL-II R = 0.13; P = 0.46) or of active VWF (SNA R = -0.2; P = 0.25 and MAL-II R = 0.13;
P = 0.46). We compared dengue patients with and without bleeding in the Jepara cohort and
did not find statistically significant differences in platelet sialic acid expression or platelet reac-
tivity (S6 Fig).
Next, we investigated mechanisms underlying desialylation. First, we tested whether plasma
sialidase activity was increased in acute dengue with a functional sialidase activity assay. As
shown in Fig 3C, sialidase activity in the plasma of acute dengue patients was not increased in
comparison to the other groups. Further proof that platelet desialylation in dengue infection
does not result from increased plasma sialidase activity was provided by mixing PRP from
healthy Dutch volunteers with PPP (1:1 volume ratio) from randomly selected patients with
dengue (sample from acute and convalescent phase), non-dengue febrile illness or healthy con-
trols (n = 6 each group). As shown in Fig 3D, no differences in platelet desialylation across the
groups were observed. Finally, to further confirm these results, we performed glycoprofiling of
intact plasma transferrin using mass spectrometry in five dengue patients with the highest
plasma sialidase activity in the functional assay [35]. Loss of sialic acid was calculated using the
ratio of the undersialylated trisialo-glycosylated transferrin form and this ratio was below the
upper reference of normal (<5%) in all five patients (Table 2).
In vitro studies
Other possible mechanisms responsible for removal of sialic acid from platelets in dengue
infection were further explored in a series of in vitro experiments. A recent study showed that
dengue virus NS1 protein is able to induce the expression of sialidase and heparanase in endo-
thelial cells, leading to desialylation of the endothelial glycocalyx layer [38]. We, therefore,
investigated whether NS1 also induces desialylation of platelets. Incubation of washed platelets
or PRP with different concentrations of NS1 up to four hours did, however, not reduce bind-
ing of SNA or MAL-II lectins to sialic acid residues, nor did it increase the binding of RCA to
galactose residues or surface expression of Neu1 on platelets indicating that NS1 did not
induce platelet desialylation (Figs 4A, 4B and S7A). As expected, desialylation was observed
using purified neuraminidase from C. perfringens as a control. NS1 did induce platelet activa-
tion, as indicated by increased P-selectin expression (Fig 4C). Next, we investigated whether
DENV itself would induce removal of sialic acid. DENV is known to activate platelets [12],
which we confirmed in our experiments by finding increased platelet P-selectin expression
(Fig 4D). However, removal of sialic acid, as evidenced by a reduction in the binding of SNA
or MAL-II, or increased binding of RCA lectin, which is a lectin that binds to desialylated β-
galactose residues, was not observed following incubation of washed platelets with DENV2 for
3 or 6 hours (Fig 4E, 4F and 4G; only data at 3 hours are shown).
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Fig 2. Increased VWF-platelet binding and plasma VWF:Ag and active VWF levels in dengue patients. (A) Platelet-VWF binding measured by flow
cytometry in unstimulated samples (line is geometric mean with 95% confidence interval) and (B) after ex vivo stimulation with increasing concentrations
of ristocetin in participants with acute dengue and healthy volunteers. (C) Time course of plasma VWF:Ag levels and (D) active VWF levels in the same
participants. (E) Pearson correlation between platelet-VWF binding and platelet number in enrolment samples and (F) fibrinogen binding after ex vivo
stimulation with high dose (156μM) TRAP in enrolment samples. Data shown are individual values or aggregated data as geometric mean with 95%
confidence interval. Differences between groups were analyzed using the Mann-Whitney U test, �P< 0.05, �� P<0.01, ���P<0.001.
https://doi.org/10.1371/journal.ppat.1007500.g002
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Next, because our clinical data showed that platelet-VWF binding is increased in dengue
infection, we explored whether VWF binding to platelets could be responsible for desialylation
Fig 3. Platelet desialylation in acute dengue and plasma sialidase activity. Binding of the lectins (A) SNA and (B) MAL-II to platelet sialic acid residues measured by
flow cytometry, in patients with acute dengue (n = 40), non-dengue febrile illness (n = 15) and healthy controls (n = 20) in Jepara. (C) Plasma sialidase activity measured
as moles of substrate (2-(4-methylumbelliferyl)α-D-N-acetylneuraminic acid) hydrolyzed per hour. (D) Binding of SNA and MAL-II lectins to platelets following
incubation of platelet rich plasma from healthy Dutch volunteers with platelet poor plasma from patients with dengue (acute and convalescence sample), non-dengue
febrile illness and healthy controls (n = 6 per group). Data expressed as geometric mean with 95% CI. Samples depicted in panels A-B were analyzed on a BD FACS
Calibur in Jepara, and samples in panel D on a Beckman coulter FC500 flow cytometry in The Netherlands, which explains the differences in MFI values. Differences
between groups were analyzed using the Mann-Whitney U test, �P< 0.05, �� P<0.01, ���P<0.001. NS depicts statistically non-significant result across groups using
Kruskal-Wallis test.
https://doi.org/10.1371/journal.ppat.1007500.g003
Table 2. Sialidase activity and plasma transferrin glycosylation of patients with dengue.
Sialidase activity (pmol/hr) Sialic acid loss (%)
Dengue patient 1 99 2.8
Dengue patient 2 101 2.6
Dengue patient 3 103 1.9
Dengue patient 4 106 3.6
Dengue patient 5 123 2.8
Sialic acid loss upper reference of normal: <5%
https://doi.org/10.1371/journal.ppat.1007500.t002
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Fig 4. Dengue non-structural protein 1 (NS1) nor dengue virus (DENV) induce platelet desialylation. Binding of
(A) SNA or (B) MAL-II lectins to washed platelets or (C) the expression of P-selectin after incubation with two
concentrations of DENV2 NS1 protein for 4 hrs at 37˚C (n = 7 platelet donors). (D) shows expression of platelet P-
selectin and (E-G) the binding of SNA, MAL-II, or RCA lectins to washed platelets following incubation with dengue
virus type 2 (DENV 2) for 3 hrs at 37˚C (n = 8 platelet donors). Purified neuraminidase from C. perfringens (100 mU)
Desialylation as a novel platelet clearance mechanism in dengue
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of platelets. To induce VWF binding to platelets, we exposed PRP of healthy volunteers to
increasing concentrations of ristocetin, which indeed resulted in a dose-dependent increase in
VWF-platelet binding (Fig 5A). In the same time, surface sialic acids were reduced as evi-
denced by a reduction in binding of the lectins SNA and MAL-II. These effects were depen-
dent on VWF binding to GPIbα as blocking the VWF with anti-GPIbα antibodies prevented
desialylation (Fig 5B and 5C). VWF-mediated platelet desialylation was confirmed using
washed platelets and purified VWF whereby addition of ristocetin resulted into exposure of
galactose residues (detected by RCA lectin binding) in a dose response manner (S7B Fig). We
further show that ristocetin-induced VWF-platelet binding increases the expression of Neu1
on the platelet surface (Fig 5D). Neu1 is stored in platelet lysosomes and the Neu1 expression
on the membrane correlated strongly (R 0.95; P = 0.01) with the lysosomal marker CD63 (Fig
5E). Previous studies showed that the neuraminidase inhibitor oseltamivir is able to inhibit
Neu1 activity in platelets [40]. We confirmed these findings by showing that ristocetin induces
the binding or RCA lectin to platelets (Fig 5F), which can be inhibited by oseltamivir acid in a
concentration as low as 1μM, which is equivalent to plasma levels of the drug [41] (Fig 5G).
Lower concentrations of oseltamivir resulted into inconsistency in the RCA lectin binding.
Discussion
In this study, we describe a new mechanism of platelet clearance and thrombocytopenia in
dengue infection. The release of VWF by activated endothelial cells results in excessive VWF
binding to platelets, leading to loss of surface sialic acid. We show for the first time that a den-
gue infection induces a marked increase in VWF binding to circulating platelets, which was
inversely related to platelet number. We further show for the first time that circulating platelets
in dengue patients have lost surface sialic acid. This occurred in the absence of increased
plasma sialidase activity. We further investigated the mechanisms underlying platelet desialyla-
tion in dengue infection in vitro and identified increased VWF binding to platelets as the most
likely mechanism. Platelets are important in preservation of endothelial integrity [10]. We
speculate that the course of events in dengue infection is that endothelial cell activation in the
setting of dengue infection leads to release and activation of VWF. The resulting VWF-medi-
ated platelet clearance may in turn contribute to the vascular leakage syndrome that is charac-
teristic of severe dengue.
We and other groups have previously shown that patients with acute dengue have higher
VWF plasma levels [19, 42]. Under normal circumstances, VWF does not bind to GPIbα on
platelets, but does so only after a conformational change exposing its active A1 domain. Active
VWF can be measured using a specific nanobody, and here, we confirm our earlier findings
that the amount of active VWF in the circulation is markedly increased in dengue infection
[19]. Our present study adds to these earlier data that we now also show directly, using a novel
flow cytometry assay, that more VWF has bound to circulating platelets. It thereby supports
the notion that VWF is important in the etiology of dengue-induced thrombocytopenia, as
binding of VWF to platelets is expected to result in platelet clearance. It is also in concordance
with our earlier observations that VWF:Ag is being consumed in children with severe dengue
[19]. In contrast to our current findings, VWF:Ag levels in these children admitted to the ICU
and the platelet agonist adenosine diphosphate (ADP) at 125 μM were used as positive controls. Mock infection with
supernatant of uninfected C6/36 cells harvested at the same time as DENV2 stocks was used as negative control. Data
are shown as geometric mean with 95% confidence interval. Samples depicted in panels A-C were analyzed on a
Beckman coulter Cytoflex, and samples in panel D-G on a FC500 flow cytometer, which explains the differences in
MFI values. Differences between groups were analyzed using the Mann-Whitney U test, �P< 0.05, �� P<0.01,
���P<0.001.
https://doi.org/10.1371/journal.ppat.1007500.g004
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Fig 5. Binding of VWF to platelets induces platelet desialylation which can be inhibited by oseltamivir. Binding of
(A) von Willebrand factor (VWF), (B) SNA and (C) MAL-II lectins to platelets and (D) platelet membrane expression
of Neuraminidase-1 (Neu-1) after exposing platelet rich plasma (PRP) of healthy volunteers to ristocetin for 1 hr at
37˚C in presence and absence of GPIb receptor blocking antibodies. (E) Pearson correlation between the expression of
Neu-1 and the lysosomal marker CD63 on the platelet membrane after incubation PRP with ristocetin (1.6mg/ml for 1
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with severe dengue showed an increasing trend towards discharge, while levels of VWF:pro-
peptide decreased. Because VWF:propeptide is secreted in equimolar amounts as VWF:Ag,
this time course was suggestive for VWF consumption. In the current study, VWF consump-
tion was probably less pronounced as most participants had dengue disease without severe
complications.
Another important finding of our study was that circulating platelets in dengue patients
contained less surface sialic acid. Removal of sialic acid exposes terminal β-galactose and β-
GlcNAc resulting in accelerated platelet clearance via Ashwell–Morell receptor [25–28].
Removal of 8–10% of platelet sialic acid was reported to be sufficient to cause platelet clearance
from the circulation [43]. Recently, VWF binding to platelets by botrocetin or by platelet
refrigeration was shown to induce unfolding of the mechanosensory domain of the GPIbα
subunit, leading to GPIb-IX–mediated signaling in the platelet, including calcium mobiliza-
tion, phosphatidylserine exposure, and likely trafficking of Neu1 to the platelet surface and
subsequent desialylation of platelet glycoproteins [29],[44]. We confirm these findings in vitro
by demonstrating that induction of VWF binding to platelets with ristocetin results in
increased expression of Neu1 on the platelet surface and platelet desialylation. We cannot
exclude that ristocetin may execute a VWF-independent effect on platelet desialylation, as pre-
vious studies suggested that ristocetin has direct effects on GPIbα and other platelet receptors
[45, 46]. However, our findings that ristocetin did not induce platelet desialylation in the pres-
ence of GPIbα blocking antibodies or in washed platelets in absence of VWF supports the con-
clusion that the effects of ristocetin on platelet desialylation are through induction of VWF
binding to platelet GP1bα. In addition, the snake venom protein botrocetin, which induces
VWF binding to platelets but does not bind GPIbα, also triggers platelet desialylation [44].
Our present study also supports findings from previous studies that platelets are activated
during a DENV infection [12, 15]. Despite our observation that activating platelets ex vivo
using ADP did not result in removal of sialic acid from the platelet membrane, we cannot
exclude that in vivo platelet activation results in trafficking of Neu1 to the membrane where it
may desialylate GP1b, leading to increased binding of VWF to the platelet.
We also investigated other possible mechanisms of platelet desialylation in dengue infec-
tion. NS1 was recently shown to induce sialidase in endothelial cells, leading to degradation of
endothelial bound sialic acid [47], but we did not find platelet desialylation upon exposure of
platelets to NS1. In addition, dengue virus does not express neuraminidase, in contrast to
other viruses as influenza or bacteria as Streptococcus pneumoniae. Incubation of platelets with
cultured dengue virus did induce platelet activation, as previously reported [12–14], but did
not induce platelet desialylation. This was further supported by the fact that sialidase activity
in plasma of dengue patients was not increased, that plasma of dengue patients failed to induce
desialylation of platelets of healthy volunteers and that plasma proteins (transferrin) of dengue
patients were not desialylated. The latter is in contrast to an earlier study by Rajendiran et al.
[48], who reported increased desialylation of plasma proteins in patients with dengue.
In vitro, VWF-induced platelet desialylation could be circumvented by the neuraminidase
inhibitor oseltamivir acid, which is widely used worldwide in the treatment of influenza infec-
tions. Interestingly, over the past years, different authors have reported that oseltamivir may
hour). (F) Binding of RCA lectin to galactose or N-acetylgalactosamine residues on platelets after exposing PRP to
ristocetin (G) with and without the addition of increasing concentration of oseltamivir. Purified neuraminidase from
C. perfringens (100mU) was used as a positive control. Data were analyzed using Student’s T-tests and presented as
geometric mean with 95% confidence interval. ��� P< 0.001, �� P< 0.005, � P< 0.05; ### P< 0.001 when samples
were compared with ristocetin-treated samples that were unexposed to oseltamivir. Data were from on 5–7 platelet
donors in� 2 independent experiments.
https://doi.org/10.1371/journal.ppat.1007500.g005
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increase platelet counts in conditions such as immune thrombocytopenic purpura [49, 50],
sepsis [51] and suspected influenza [52]. We are currently carrying out a phase 2 randomized
clinical trial to study the effect of oseltamivir on thrombocytopenia and plasma leakage in den-
gue infection (ISRCTN35227717). In addition, antagonists of VWF, such as the anti-VWF
aptamer ARC1779 are nowadays available. ARC1779 was able to reverse thrombocytopenia in
VWD type 2B, a condition characterized by excessive binding of VWF to platelets [53]. This
reinforces the importance of VWF in platelet clearance and supports the possible use of VWF
antagonists as adjunctive therapy for dengue-associated thrombocytopenia.
Our present study confirms our earlier finding that acute dengue infections are not only
associated with thrombocytopenia but also platelet dysfunction with hyporeactivity to ex vivo
activation [15]. This platelet dysfunction, which may contribute to bleeding complications,
may be a consequence of profound platelet activation in the circulation resulting in secondary
loss of function. Additional proof for the occurrence of platelet exhaustion in dengue infection
was recently provided by a quantitative proteomics study of platelet contents showing exhaus-
tion of the granule-stored PF4/CXCL4 [54]. Gain of function mutations in VWF, as seen in
von Willebrand disease type 2B were shown to impair activation of the αIIbβ3 integrin. How-
ever, this mechanism appears to be less important in dengue infection, as there was no inverse
correlation of platelet-VWF binding with platelet-fibrinogen binding in our cohort.
Different limitations of our studies should also be acknowledged. First, VWF binding to
platelets and platelet sialic acid were measured in different cohorts, preventing us to analyze a
direct correlation between both parameters. We were able to correlate platelet SNA and
MALII lectin binding with plasma levels of active VWF, but this did not show a significant cor-
relation. In our opinion, however, this does not disprove the hypothesis that excessive platelet-
VWF binding is responsible for platelet desialylation in dengue infection, because VWF bind-
ing to platelets did not correlate with active VWF plasma levels in our cohort. Second, it was
not possible to measure the expression of Neu1 on the platelet membrane in the patient sam-
ples. Third, the proposed mechanisms for platelet desialylation were analyzed using in vitro
studies and samples from healthy individuals, rather than dengue-infected patients due to lim-
ited availability of patient material.
In conclusion, acute dengue infections induce the binding of VWF to platelets, which
results in the removal of sialic acids from the platelet surface by the actions of endogenous
neuraminidase. Neuraminidase inhibitors such as oseltamivir might represent a novel thera-
peutic option for dengue-associated thrombocytopenia.
Supporting information
S1 Fig. Platelet activation with impaired reactivity to TRAP in patients with acute dengue.
Binding of fibrinogen to platelets and platelet P-selectin expression in unstimulated samples
and after ex vivo stimulation with two concentrations of TRAP. (A, B) Data from Bandung
cohort with longitudinal data from the different days of fever in dengue patients and in healthy
controls. Platelet P-selectin expression and binding of fibrinogen were measured using flow
cytometry and are expressed as median fluorescence intensity (MFI) in arbitrary units. Data
depicted as geometric mean with 95% confidence interval. Differences between groups were
analyzed using the Mann-Whitney U test, �P< 0.05, �� P<0.01, ���P<0.001.
(DOCX)
S2 Fig. Flow cytometry gating strategy for determination of VWF binding to platelets.
Platelets were gated based on forward and side scatter characteristics (A), followed by positiv-
ity for the platelet marker CD61-PC7 (B). The Median fluorescence intensity (MFI) of anti-
VWF after stimulation (C) without agonist and (D) after ex vivo VWF-activation with
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ristocetin (0.777 μM). (E) Observed differences in VWF binding to platelet with marker Anti-
VWF-FITC in unstimulated sample and after ex vivo stimulation of 0.777 μM.
(DOCX)
S3 Fig. ADAMTS-13 activity in Bandung cohort. (A) Data from different days of fever in
dengue patients and in healthy controls. Data are shown as geometric mean with 95% confi-
dence interval. Differences between groups were analyzed using the Mann-Whitney U test.
(B-D) The correlation between VWF binding to platelets without any agonist stimulation and
plasma VWF, VWF activation factor and ADAMTS13 activity is shown. Analysis were done
using Pearson correlation coefficient. �P< 0.05, �� P<0.01, ���P<0.001, ���� P<0.0001.
(DOCX)
S4 Fig. Differences in platelets and VWF parameters between dengue patients with and
without bleeding, and patients with and without plasma leakage. Data shown are platelet
numbers (A and B), VWF binding to platelets in the absence of an agonist (MFI) (C and D),
Plasma VWF:Ag levels (E and F) and plasma active VWF levels (G and H). Differences
between groups were analyzed using the Mann-Whitney U test, �P< 0.05, �� P<0.01,
���P<0.001.
(DOCX)
S5 Fig. Flow cytometry gating strategy for determination of sialic acid expression on plate-
lets. Platelets were gated in P0 based on forward and side scatter characteristics (A) followed
by positivity of the platelet marker CD61-PC7 in P1 (B). The median fluorescence intensity
(MFI) of PE-labeled SNA lectin on platelets is determined from gate P1 (C, higher expression,
and D, lower expression of sialic acid).
(DOCX)
S6 Fig. Sialic acid expression and platelet reactivity in dengue patients with or without
bleeding. Binding of the lectins (A) SNA and (B) MAL-II to platelet sialic acid residues were
measured by flow cytometry in dengue patients with (n = 22) and without bleeding (n = 18).
Platelet P-selectin expression and binding of fibrinogen to platelets in unstimulated samples
and after ex vivo stimulation with two concentrations of ADP (C, D). Platelet P-selectin
expression and binding of fibrinogen were measured using flow cytometry and are expressed
as median fluorescence intensity (MFI) in arbitrary units. Data are expressed as geometric
mean with 95% CI. Differences between groups were analyzed using the Mann-Whitney U
test, �P< 0.05, �� P<0.01, ���P<0.001.
(DOCX)
S7 Fig. Platelet desialylation is mediated by VWF binding to platelets. (A) Expression of
Neuraminidase 1 (Neu-1) and binding of RCA lectin and VWF to platelets after incubation
with two concentrations of DENV NS1 protein for 4 hrs at 37˚C (n = 7 platelet donors). (B)
Binding of VWF and RCA to platelets after incubating washed platelets with increasing con-
centrations of purified VWF and 1.6mg/ml of ristocetin for 1 hr at 37˚C (n = 5 platelet
donors). Purified neuraminidase from C. perfringens (100 mU) was used as positive control.
Samples were analyzed using Beckman coulter Cytoflex flow cytometry. Data are shown as
geometric mean with 95% confidence interval. Differences between groups were analyzed
using the Mann-Whitney U test, �P< 0.05, �� P<0.01, ���P<0.001.
(DOCX)
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